NCT04453046 - Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

November 14, 2022

Study Completion Date

November 14, 2022

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DEVICE

Hemopurifier

Two Hemopurifier treatments on Day 1 and Day 21

DRUG

Pembrolizumab 200mg IV

Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles

Trial Locations (1)

UPMC Hillman Cancer Center, Pittsburgh